SUMMARY
Introduction
Leishmania spp are protozoan parasites of the Trypanosomatidae family that cause disease in humans and animals. In general, infections with these parasites can be divided into three main forms namely, cutaneous (CL), mucocutaneous (MCL) and visceral (VL) (or kala azar) leishmaniasis [1] . The disease is prevalent in many tropical and subtropical regions of the world, where it is transmitted via the bite of an infected sand fly. Although leishmaniasis is endemic in 88 countries, 90% of CL cases have been reported in Afghanistan Syria, Saudi Arabia, Brazil, and Peru. VL, also known as kala azar, is the most dangerous form of the disease and occurs in Bangladesh, Brazil, India, and Sudan. A new syndrome in which Leishmania co-infects patients with AIDS is particularly deadly and has been reported in 33 countries including Kenya [1, 2] . The impact of leishmaniasis on humans is enormous. One tenth of the world's population is at risk and 2 million new cases are reported each year [1] . There are 22 species that cause disease in humans or animals [3] and specific
Epidemiology of leishmaniases in Kenya
Leishmaniasis has been known to be endemic in parts of Kenya from as far back as early in the 20 th century [6] . An outbreak of VL in the King's African Rifles troops encamped north of Lake Turkana in southwest Ethiopia was reported in the 1940s [7] . Since then Turkana, Baringo, Kitui, Machakos, Meru, West Pokot and Elgeyo Marakwet districts have been considered to be endemic for kala-azar. Between 1950 and 1960 more than 1,052 cases of VL were reported from these districts alone [6] .
A serious outbreak of VL was reported in Kitui district that began in 1952 with 303 cases being reported and peaked in 1953 with 2,142 cases. In the same year 157 cases were reported in the neighbouring Meru district [6] . Another outbreak of VL in Meru district was reported in 1966 with 1,500 cases [8] . Phlebotomus martini Parrot, 1936 was shown to be the vector of kala-azar during that epidemic [9, 10] . Further outbreaks of VL were reported in Machakos district in the 1970s, and again in Kitui district in the 1980s [11] [12] [13] . Baringo and the neighbouring districts such as West Pokot were first identified as leishmaniases foci in 1955 [14] . Since then, L. donovani transmitted by P. martini and L. major transmitted by P.
duboscqi Neveu Lemaire, 1906 have been shown to exist in the region allopatrically, with rodents being the reservoir of CL (15-21). Other possible vectors that have been reported include P. celiae Minter, 1962, P. vansomeranae Heich, Guggisberg et Teesdale, 1956 and Sergentomyia garnhami [22] for VL [23, 24] . VL caused by L. donovani, is endemic in Baringo District, Kenya. The disease occurring in Baringo has a focal distribution in the dry, hot areas below 1500 metres and the infections may be characterized as follows: 1) asymptomatic 2) subclinical and self-limiting (not medically identifiable), and 3) clinically manifest disease (that is medically identifiable). Half of the reported VL patients are between 5 and 14 years of age and 66% of them are males. A human case of a mixed L. donovani and L. major infection has been reported in this dual focus of VL and CL [25] . Often associated with sporadic incidents of the disease rather than epidemics, as many as 305 cases of VL were reported in Baringo district alone in 1999 [26] [27] [28] [29] The following sections summarize research activities on leishmaniases in Kenya in which KEMRI has been a major contributor.
Characterization of Leishmania species in Kenya
It is essential to know the identity of the parasite(s) in each focus, since this knowledge has implications for control and treatment of leishmaniases [42] 
Research on sand fly biology and control in Kenya
Control of phlebotomine sand flies remains a difficult problem throughout the world because of the insects' very highly specialized breeding sites. Use of insecticides remains the most effective method of sand fly control. However, resistance to insecticides has proved to be a major challenge. Use of bed nets or permethrin impregnated wall cloth, repellents and other personal protective measures have proved to be unreliable in Kenya [45] . With these shortcomings, there is need to identify new insecticides.
In general, control of leishmaniasis is hampered by the diversity of vectors, parasites, and reservoir hosts and the interventions must take into account these differences. It is therefore crucial to understand the biology of the leishmaniasis as well as that of the sand fly. The exploration of host-parasite interactions between species of Leishmania and respective vectors represents a wide and important field for basic and applied research as well. To address these needs, laboratory reared sand fly colonies have been established at KEMRI. These include P. martini and P. duboscqi Neveu-Lemaire (Diptera: Psychodidae) [17] . It is through studies done using P. duboscqi that L. major development within the sand fly was unravelled [46] . These studies have shown that it takes a period of 4-25 days, for the parasite to develop inside the sand fly and during the next blood meal the infective metacyclic stage enters the body of host through a sand fly bite [46, 47] . At least five developmental forms have also been recognized during development in the subgenus Leishmania, namely, procyclic promastigotes, nectomonad promastigotes, haptomonad promastigotes, paramastigotes, and metacyclic promastigotes [46] .
Understanding of sand fly biology is also important in designing new control programmes in leishmaniases. It has also been shown that P. perniciosus can acquire and allow the development of L. infantum by feeding on L. infantum/HIV coinfected patients. Since this sand fly is an important vector of VL in southern Europe, a new natural anthroponotic cycle could be considered in the epidemiology of L. infantum /HIV coinfection [48] . This phenomenon is known as xenodiagnosis and this technique has been shown to be able to detect the presence of Leishmania parasites in a patient that other conventional diagnostic techniques failed (48). Therefore, the design of leishmaniasis control programs and the management of coinfected individuals should take these findings into account in southern Europe [48] .
Investigations on vectors of leishmaniases in Kenya started only in the early 1950's when the VL assumed importance as a result of a major disease epidemic outbreak [49] . Since then these investigations on vectors have resulted in identification of the main vectors for both VL and CL. P. martini Parrot has been confirmed as the vector for L. donovani the aetiological agent of VL in Kenya, southern Sudan, and Ethiopia [15, 21, 50] . This sand fly species rests and breeds in termite hills, animal burrows, tree holes, and house walls [51, 52] . It feeds mainly on goats, rabbits, and humans, and to a lesser extent on dogs, cattle, and other hosts [52] . Another vector for L. donovani in Kenya is P. orientalis which occurs in Kajiado district of Kenya [30] .
Among the cutaneous forms of leishmaniasis P. duboscqi Neveu-Lemaire (Diptera: Psychodidae) has been confirmed as the main vector of L. major in West Africa and the Rift Valley of Kenya [53, 54] . P. pediffer, P. longipes and P. elgonensis have been implicated as vectors of L. aethiopica occurring in the vicinity of Mount Elgon, Kenya [32, 34, 55, 56] . P. guggisbergi has been incriminated as a vector of L. tropica endemic in Samburu, Laikipia, Narok, Nakuru and Nyandarua districts of Kenya [37, 40] .
Research on animal reservoirs of Leishmania in Kenya
Extensive research has been carried out in eastern Africa for animal reservoirs of both VL and CL. The domestic dog [54] 
Research on new diagnostic tests for leishmaniases
Sensitive, specific, reproducible, feasible and cheap diagnostic tests are needed if one wants to build an effective and efficient testtreatment strategy [63] . Since Leishman identified the parasite in 1901, the definitive diagnosis of VL has relied on demonstrating the organism by microscopy in smear or culture of aspirates or tissue [64, 65] . However, a splenic-aspiration technique [66] which is used to acquire these tissues can hardly be recommended for rural district hospitals because of the risk of fatal haemorrhage, which subsists even with the recently introduced safer procedures [67] . Therefore, the search for a suitable alternative for splenic aspirates is thus still going on.
Over the past 20 years, several serological tests have been developed showing high sensitivity for visceral disease [68] . Enzyme linked immunosorbent assays (ELISA) for detecting leishmanial antibodies has also been established and successfully applied in clinical routine and seroepidemiological surveys in Kenya [26, 27, 69] . Of all the available serological tests, the direct agglutination test (DAT) has proved to be the most appropriate one for field use in Kenya [29, 63, 70, 71] .
Other methods that have been tested include isoenzyme analysis [72, 73] ; kDNA based techniques [74, 75] . In recent years polymerase chain reaction (PCR) techniques for leishmaniases have been developed and applied to visceral disease with contradictory results [76, 77] . Apart from the fact that PCR does not eliminate the need for tissue sampling, it is not exactly the type of appropriate technology needed in endemic areas.
Research on new treatment strategies and chemotherapeutic agents for leishmaniases
Neglected diseases such as leishmaniasis, trypanosomiasis, Chagas disease, and malaria have had a devastating impact on the world's poor. These treatable, infectious tropical diseases have been progressively marginalized by those in charge of making research programme decisions, both in the public and private sectors. Unfortunately, people suffering from these diseases do not constitute a market lucrative enough to attract investment in research and development for new drugs. KEMRI is a founding partner of an international effort, Drugs for Neglected Disease Initiative (DNDi), whose aim is to address lack of new or improved drugs for neglected diseases such as leishmaniasis. KEMRI's Centre for Clinical Research (CCR) brings to DNDi a rich history of involvement in tropical diseases and expertise in clinical research for neglected diseases.
Over the last 25 years, scientists at CCR have been addressing the issue of treatment options for Kala-azar. The treatment of leishmaniasis, as currently conducted in Kenya with sodium stibogluconate, is unsatisfactory as it is expensive, resistance and relapses may occur [78] . However, it is through collaborative efforts of CCR scientists several new drugs or including AmBisome ® a safer and more effective lipid formulation of Amphotericin B (second line VL treatment); sitamaquine and aminosidine, alone or combined with sodium stibogluconate, in visceral leishmaniasis, compared to treatment by stibogluconate alone have been tested [79] .
Worldwide, Leishmania parasites are increasingly becoming more and more resistant to antileishmanial drugs. The increment of in vitro antimony resistance due to intermittent drug exposure [80] [81] [82] [83] , the isolation of antimony-resistant Leishmania strains from patients with unresponsive CL [84, 85] , and recent reports, of numerous cases of VL among patients with the human immunodeficiency virus [86] [87] [88] [89] indicate the need for new therapeutic agents for control and management of leishmaniases. Extensive studies of new drugs with antileishmanial activities, including natural products and synthetic compounds, have been undertaken worldwide [90] , but problems associated with the currently available drugs remain unresolved. In recent years, there has been growing interest in alternative therapies and use of natural products, especially those derived from plants [91] . The use of plantbased medicine for healing and prophylaxis is as ancient and universal as medicine itself. Recent research undertaken in KEMRI has led to discovery of plant-based products with antileishmanial activities. For instance, studies have shown that leaf, root and stem extracts from Ajuga remota and Trichilla emetica have antileishmanial activity when tested against L. donovani in vitro and in vivo [92] . Some of the active compounds isolated from plants include iridoid glucosides, limonoids and terpenoids [92] . KEMRI has also initiated studies aimed at testing extracts/compounds from medicinal plants used widely by the local people for treating splenomegaly related ailments in leishmaniasis endemic areas of Kenya [92] . A long term goal of this research is to develop oral drugs for leishmaniases. These drugs have an advantage of reducing treatment-related socioeconomic difficulties (inadequate health care infrastructure and the long period of patient hospitalization) prevalent in the endemic areas.
Among the products tested for antileishmanial activity in the rodent models (BALB/c mice and Syrian hamsters) at KEMRI includes metal ion chelators namely (Pristane, EGTA, and HEEDTA). Results of these studies suggests that metal ions chelators have antileishmanial potential in vivo against L. donovani but their activity was low compared to that of Pentostam [93, 94] .
Vaccine related research for leishmaniases in Kenya
Currently there is no vaccine available for use against any form of leishmaniases worldwide [41] . In brief, vaccines based on killed promastigotes with or without Mycobacterium bovis BCG have shown significant protection against L. braziliensis [95] , L. mexicana or braziliensis, L. major [96] and L. donovani [97] in humans. In experimental animal models, several other vaccine preparations are being tested. Examples include: attenuated live parasites [98] ; subunit vaccines delivered by live carriers such as BCG expressing the surface protease gp63 of L. major [99] ; vaccinia virus expressing the glycoprotein gp46/M2/PSA-2 [100]; gp63 expressed in attenuated Salmonella typhimurium [101] ; purified recombinant or native proteins formulated with an adjuvant such as the Leishmania-homologue of receptors for activated C kinase (LACK) plus IL-12 [103, 102] , gp46/M2/PSA-2 or protein dp 72 plus Corynebacterium parvum [104] , T cell epitopes plus Poloxamer 407 [104] ; and vaccination with DNA encoding gp63 [105] , LACK [106] , or gp46/M2/PSA-2 [107] . In general, these vaccination protocols elicited partial protection against L. major.
Vaccine research at KEMRI is still at the rodent model stage of development in leishmaniases. So far live-attenuated L. major parasites [108] , L. major culture-derived soluble exogenous antigens (SEAgs) [109] , lipophosphoglycan (LPG) alone or LPG plus Mycobacterium bovis Bacille Calmette-Guerin (BCG) [110] , and LPG plus salivary gland lysates [111] have been tested.
Transmission blocking vaccine studies in leishmaniasis have also been undertaken at KEMRI. These studies have shown that LPG is an excellent candidate as a transmission blocking vaccine against L. major infections [112, 113] . In these studies, sand flies, which fed on BALB/c mice, immunized with L. major-derived LPG [114] or monoclonal antibodies raised against LPG [115] showed that parasite development was inhibited at the log phase (procyclic) of the parasite. There was also a marked reduction in the numbers of metacyclic promastigotes developing, leading to reduced transmission of L. major to naive BALB/c mice [113] . It has also been shown that P. duboscqi gut lysates and proteins present in L. major-derived LPG share two common proteins of molecular weights 105 kDa and 106 kDa [115] . The goal of these studies has been to develop a vaccine that can be utilized both to reduce transmissible infections within the sand fly and disease severity within the host. Some of the important findings relevant to vaccine research also include the determination of an inoculum dose required for effecting a visceral infection in rodents [116] .
At the Institute for Primate Research (IPR) in Karen, Nairobi it has been shown that the vervet monkey (African Green monkey) is a good model for human cutaneous or visceral leishmaniases [117, 118] 
Conclusion
Although various aspects of the transmission and control of leishmaniases have been studied in Kenya, the impact of visceral leishmaniasis or kala azar is still enormous in Kenya. Control measures against sand flies and reservoir hosts need to be further evaluated in terms of their effect on disease incidence. Very few attempts have also been made to quantify local factors or to identify the causative mechanisms of epidemics in previously nonendemic or low endemic areas. Research to develop more effective drugs that meet the current standards of safety also remains a high priority. It is hoped that the entry of Drugs for Neglected Disease Initiative (DNDi), whose aim is to address lack of new or improved drugs for neglected diseases including leishmaniases will mobilize inter-country, international support and collaboration in terms of both finance and technical expertise towards achieving this goal. Diagnostic and vaccine-related studies are also still required to be pursued vigorously.
Many cases of leishmaniases still go unreported or undiagnosed hence the official statistics are currently not available for determining the actual number of cases in Kenya. Health education activities are still required to sensitize people living in endemic areas, medical and public health managers, and individuals at risk on leishmaniases. Decision makers should be sensitized on the importance of the leishmaniases as a public health problem so that they will support and defend control programmes. Notwithstanding these challenges, contributions from KEMRI and its partners towards leishmaniases control in Kenya and the eastern Africa region is commendable. 
